#SynBio团队 | 倪俊 木质素价值化对于实现经济可行和可持续的木质纤维素生物精炼厂至关重要。近年来，木质素及其水解芳烃的生物利用 引起了广泛关注，这是实现零浪费和经济可行的生物精炼厂的关键。然而，对昂贵辅因子（例如，三磷酸腺苷 （ ATP ）、还原烟酰胺腺嘌呤二核苷酸磷酸 （ NADPH ） 和辅酶 A （ CoA ））的持续需求严重阻碍了木质素可持续地转化 为有价值的产品。为了减轻这种限制，一种可能的方法是引入辅助辅因子再生酶，这通常需要精确调节辅因子代谢网络 以防止细胞稳态的破坏。 此外，生物合成机械和辅因子再生系统之间催化活性的不平衡是有效转化的关键障碍，导致木质素有价值的分子的产量 极其有限。例如，来自木质素衍生的对香豆酸 （ pCA ） 的覆盆子酮 （ RK ） 的生产率低于 0.003 g l h ，转化率仅 为 11.3% ，姜黄素的生产率限制为 0.006 gl h 。 目前，没有通用的解决方案可以同时克服昂贵的辅因子需求和不平衡的酶活性。 因此，开发一种改善木质素生物转化途 径的通用策略是 可取的。 【SynBioCon】 获 悉， 上海交通大学倪俊 团队于 2025 年 5 月在期刊 ...

本次行动的核心任务，是在三年内帮助各类人群树立科学的体重管理观念，切实降低肥胖及相关慢性疾病的发病率。 ▍国人超重肥胖现象 《中国居民营养与慢性病状况报告》数据显示： 以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 2025年3月9日，国家卫生健康委员会正式拉开了为期三年的"体重管理年"专项行动，旨在以科学减重和健康生活方式，积极应对我国不断加剧 的超重与肥胖难题。 我国6-17岁青少年儿童中，超重和肥胖比例已高达19%；成年人群的超重肥胖率更是达到50.7%。 过去15年，青少年肥胖率激增了12倍，职场人士"过劳肥"以及老年人肥胖问题也日益严重。肥胖不仅影响外观，还与高血压、糖尿病、心脑血 管疾病等多种慢性病紧密相关。这些慢性病的医疗负担占全国疾病总负担的70%以上，直接医疗支出每年超过2400亿元。 如何判断肥胖？ 主要依据BMI和腰围等指标。 BMI（体质指数）=体重（kg）÷身高（m）²，正常范围为18.5～23.9。 例如，身高1.66米、体重56公斤，则BMI=56÷（1.66×1.66 ...

Core Viewpoint - The article highlights the issues surrounding the marketing and sale of overseas dietary supplements in China, particularly through private domain shopping platforms like VTN, which are often associated with misleading claims and lack of regulatory oversight [2][22][27]. Group 1: Company Overview - VTN and ABM are subsidiaries of ACCESS Group, which focuses on health and beauty products through a network of global brands and social media marketing [7]. - VTN operates as an international brand membership club for consumers, while ABM serves as a platform for light entrepreneurship, allowing individuals to become distributors without holding inventory [7][21]. Group 2: Marketing Practices - The marketing strategies employed by VTN include exaggerated claims about product efficacy, such as improving immunity and treating chronic diseases, often presented in a misleading manner [4][8]. - Distributors utilize a combination of educational content and product promotion to appeal to consumer pain points, often using social media and live streaming to reach potential buyers [8][10]. Group 3: Regulatory Issues - There are significant regulatory gaps in the oversight of cross-border e-commerce, particularly regarding the promotion of dietary supplements that are not registered or approved in China [2][22][27]. - The lack of Chinese labels on many products sold through VTN raises concerns about transparency and consumer understanding of the ingredients and potential health risks [4][22]. Group 4: Consumer Experience - Consumers face challenges in returning products purchased through VTN, as many items do not support a seven-day return policy, complicating the process of addressing quality concerns [25][26]. - Complaints regarding product quality and after-sales service have been reported, indicating a need for improved consumer protection measures in the cross-border e-commerce sector [25][26].

在天开园6号楼，天津久瑞盛科技有限公司的员工们正专注地投身于科研工作。该公司是南开大学化学 学院赵国锋教授创办的企业之一。从最初在实验室反复验证理论、攻克技术难关，到如今将科研成果转 化为实际生产力，赵国锋团队不仅迈出了科研创新的坚实步伐，更朝着产业报国的目标不断前行，成为 高校科研成果转化的生动典范。 产业觉醒：高端光引发剂国产化替代 为解决这一技术难题，久日新材制定了以"光固化产业为核心、半导体产业为重点"的发展方向。该公司 累计投入5亿元，在天津成立半导体化学材料研发平台——天津久日半导体材料有限公司，并在江苏徐 州建成年产600吨光刻胶专用光敏剂PAC生产线和年产4500吨光刻胶生产线，部分产品已实现规模化生 产。 赵国锋对未来充满信心："久日新材将以光刻胶所用的光敏剂和光引发剂为原点，与上下游企业一道， 围绕高端光刻胶及配套材料进行研发生产，打通半导体光刻胶及其相关电子级原材料生产的产业链。" 我国高端光引发剂材料曾长期依赖进口，而这类用于新型环保紫外(UV)涂料、UV油墨的关键材料，直 接关系到包装印刷、电子制造、新型材料等产业链的安全。1998年，在南开大学有机化学实验室深耕多 年的赵国锋教授不 ...

Core Insights - Julydeer® is a dietary supplement brand founded in 2012 in Colorado, USA, focusing on "scientific, rigorous, innovative, and safe" principles in its product development and manufacturing [1] - The brand emphasizes technological innovation and has established a comprehensive R&D and production system for dietary supplements, ensuring product safety and efficacy through various certifications [1] - The company combines traditional herbal wisdom with modern scientific research, adhering to evidence-based medicine principles in its product formulations [1] Product Range - **Liver Protector: Milk Thistle Hard Capsules** - Contains 10,000mg of North American wild milk thistle seeds and 500mg of concentrated silymarin extract per serving - Designed for individuals with liver damage from alcohol, fatty liver, or abnormal liver indicators, showing clinical evidence of improving liver function [2] - **Cardiovascular Shield: Natto Hard Capsules** - Contains 150mg of natto kinase per bottle, supporting cardiovascular health with a gentle and safe thrombolytic effect [2] - **Krill Oil Soft Capsules** - Contains 1,000mg of Antarctic krill oil, enhancing Omega-3 absorption and showing significant effects on blood lipid regulation [3] - **Fish Oil Soft Capsules** - Contains 400mg of DHA and 100mg of EPA, supporting brain and eye health, particularly beneficial for children's brain development and elderly cognitive maintenance [4] - **Joint and Respiratory Health: Quercetin Hard Capsules** - Demonstrates a 15% reduction in blood uric acid levels and a 35% decrease in gout attack risk [6] - **Anti-Aging and Immune Support: PQQ Collagen Hard Capsules** - Activates mitochondrial function and reduces oxidative damage to skin cells [7] - **Astaxanthin Soft Capsules** - Features a patented extraction method that improves absorption by 260%, significantly enhancing its antioxidant effects [8] - **Women's Multivitamin Tablets** - Provides a comprehensive nutrient profile to improve hair loss and enhance immunity [9] - **Brain Health and Sleep Management: Phosphatidylserine Hard Capsules** - Supports cognitive function and alleviates anxiety, particularly beneficial for students and high-pressure workers [14] Brand Positioning - Julydeer® aims to redefine dietary supplements with a focus on "precision nutrition," adhering to high standards of purity, concentration, absorption, and transformation [1] - The brand's claims are supported by scientific literature, avoiding absolute terms and disease treatment claims, thus ensuring compliance with advertising laws and health food regulations [1]

"倘若我们能给予每个人恰到好处的营养和锻炼， 既不过量也不不足， 我们就找到了通往健康的最安全途径。" 古希腊名医希波克拉底 一 我们常以为衰老是岁月不可抗拒的结果，但科学家们发现，在这些表象背后潜伏着一个加速衰老的幕后 推手——慢性炎症。 发表在《Nature Aging》杂志上的研究为炎症如何催生衰老提供了关键线索。 该研究由美国弗吉尼亚大学的Desai团队完成，发现巨噬细胞（一种免疫细胞）的线粒体随着年龄增长 逐渐丧失摄取钙离子的能力，而这种钙信号功能的下降会引发免疫系统的慢性激活。 由于线粒体无法有效"储存"钙离子，细胞内钙信号变得过度活跃，从而持续开启炎症通路NF-κB。 研究人员形象地将这一系列变化描述为"线粒体钙信号障碍→免疫系统慢性激活→炎症性衰老" 。 这一定位于巨噬细胞内部的分子故障，被视为驱动身体慢性炎症的"火种"。 二 慢性炎症就像一把钝刀，日积月累地侵蚀身体各个系统。 首先，在大脑中，炎症因子可以通过血脑屏障，引发神经炎症，长期导致神经元损伤，加速大脑退化。 研究显示，慢性炎症水平升高会增加阿尔茨海默症等神经退行性疾病的发生风险。很多老年人的认知能 力下降都与体内持续的低度炎症状态有 ...

Core Viewpoint - The company reported a slight decline in revenue but a significant increase in net profit and earnings per share, indicating strong operational efficiency and profitability despite revenue challenges [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 1.716 billion yuan, a year-on-year decrease of 0.9% [1]. - The net profit attributable to shareholders was 109 million yuan, reflecting a year-on-year increase of 183.7% [1]. - Basic earnings per share (EPS) reached 0.2266 yuan, up 212.6% year-on-year [1]. Business Segment Analysis - The cottonseed business has returned to normal operations, while the plant extraction business has exceeded expectations [2]. - The plant extraction segment generated revenue of 867 million yuan, a year-on-year increase of 13.8%, with a gross margin improvement of 2.15 percentage points [2]. - The cottonseed segment reported revenue of 760 million yuan, a year-on-year decrease of 9.5%, with a gross margin of approximately 6.1% [2]. Market Strategy - The company adopted a strategy of "price for volume," leading to increased sales volume and revenue growth in various product lines [3]. - The price of chili red pigment significantly decreased, resulting in a revenue increase of approximately 7% due to volume elasticity [3]. - The company capitalized on domestic raw material cost advantages to expand into overseas markets, with chili extract sales doubling and contributing to a revenue increase of about 24% [3]. Long-term Outlook - The company is focused on long-term advantages, expanding overseas planting bases, and making breakthroughs in new businesses such as traditional Chinese medicine and health products [3]. - The company anticipates maintaining high growth rates in performance as major products return to a cyclical uptrend [3]. Investment Recommendation - The company is a leading player in the plant extract sector, with stable profitability in key products and a strong growth trajectory in market share [4]. - The ongoing construction of the Zambia plantation is expected to further reduce costs, and the health product business shows significant potential for growth [4]. - Projected EPS for 2025-2027 is 0.67, 0.83, and 1.00 yuan, with corresponding price-to-earnings ratios of 16.3X, 13.1X, and 10.9X, maintaining a "buy" rating [4].